I believe everyone is not unfamiliar with Ebike Motors. According to the different position characteristics they are used on bicycles, there are no more than three common types. One is the Central EbikeMotor commonly used on mountain assisted bicycles. Given the characteristics of mountain Electric Bikes, riders need to quickly receive the assistance of an electric motor during their uphill and downhill journey in a very short amount of time. The central electric motor precisely fits this characteristic. As long as the foot is stepped on it, the motor will enter a working state, providing necessary strength support for riders, making outdoor mountain cycling particularly enjoyable and free. Another type is the rear wheel hub motor and the front wheel hub motor, which are commonly used on urban series power assisted bicycles. Because the most common time for people to ride in the city is during commuting to and from work, commuting to and from school, and ending a tiring day of work. Riding a favorite power assisted E Bike not only saves effort but also avoids the troubles caused by road traffic congestion. Lithium battery assisted bicycle operation with rear wheel hub Motor. Rear Hub Motor,Front Hub Motor,Hub Motor Ejoysport Technology (SuZhou)Co.,LTD , https://www.yqejoysport.com
At the same time, some analysts speculated that a number of pharmaceutical giants are likely to acquire Bayer, and Pfizer and Novartis are the most likely.
The possible huge mergers and acquisitions will change the landscape of large pharmaceutical companies.
The analysis of mergers and acquisitions assessment tools of Evaluate Pharma, a UK pharmaceutical and biotech industry forecasting and analysis company, revealed that if there are any giant merger and acquisition intentions among these pharmaceutical companies’ internal executives, the top three pharmaceutical companies in 2014 may be: Novartis - Bayer, Sanofi-Schweberg and Roche.
Super Mix 1: Novartis-Alcon
EvaluatePharma's latest analysis and forecast shows that if Novartis continues to acquire another 52% of Alcon from 2010, Novartis will surpass Roche in 2014 to rank first in the world.
This means that Novartis will hold a 77% stake in the Swiss eye care company, and will therefore merge Alcon's total prescription drugs and OTC sales revenue, which is similar to Roche's merger of Genentech's sales.
Super combo 2: Novartis-Bayer
German group company Bayer is one of the most widely-owned companies in its group of companies. Its business scope includes healthcare, diagnostics, agrochemicals, and industrial chemicals. Last year, prescription drugs and OTC sales were US$16.3 billion, accounting for only the total number of companies. 37% of sales ($44.4 billion).
Many people in the industry believe that the biggest obstacle to the purchase of Bayer is the issue of time and price. Once the purchaser separates the other business of the group company for the pursuit of a single healthcare business, there will be a difficult price issue - the company still strongly opposed the separation of the company's business, which may deter potential buyers. Super combo 3: Pfizer - Bayer
No M&A forecast will lack Pfizer. Regardless of whether the mergers and acquisitions of pharmaceutical companies are large or small, like some observers, they still expect the U.S. pharmaceutical giants to resolve the difficulties caused by the expiration of their main product patents through patents. The period will allow Pfizer to drop from the first place last year to sixth place in 2014.
At the moment, many rumors have once again linked Pfizer and Bayer.
Contrary to Novartis, Pfizer hopes to concentrate all its energy on medicine. Pfizer demonstrated this by selling its consumer health products business to Johnson & Johnson for $16.6 billion last year. This shows that the acquisition of Bayer will represent a major shift in strategy for the US pharmaceutical giant, which will be difficult to obtain shareholder approval.
Super Combination 4: Sanofi-Squibb
Information about the merger of Sanofi-Aventis and its key partner, Bristol-Myers Squibb (BMS), has been circulating for many years. The two companies collaborated on the development of two blockbuster-class products: the anticoagulant Plavix (Plavix, clopidogrel) and the hypertensive drug Avapro (irbesartan). The problem for BMS is that the company’s best-selling drugs last year will expire in 2011 and 2012, respectively.
Due to the failure of BMS to acquire ImClone, the rumors of the recent acquisition of BMS by Sanofi-Aventis have intensified. The focus is on BMS’s sale of 17% of British Columbia’s equity to obtain US$1 billion. This means that the value of the BMS company will be reduced by 1 billion US dollars. Conclusion
Since Sanofi-Synthelabo’s acquisition of Aventis for $63 billion in 2004, there have been no new giant M&A transactions between major pharmaceutical companies. Therefore, it is understandable to some extent why these merger rumors currently appear.
Big pharma companies are facing the biggest challenge the industry has ever faced. It may be somewhat attractive to ensure that it is in the industry by mega-mergers. In addition, it is now in a period of financial crisis. The pharmaceutical industry may be the only industry that may be fulfilled in merger rumors. Because large pharmaceutical companies have sufficient cash in their hands, Pfizer, for example, has a $26 billion contingency fund.
However, rumours can only be rumors for the time being. Most large pharmaceutical company executives have opposed large-scale mergers and acquisitions, because it turns out that such giant mergers and acquisitions will only weaken the value of the company.
According to the analysis of the latest financial situation of the Big Pharmaceutical Company, in the recent rumors of mergers and acquisitions, the mergers and acquisitions between Sanofi-Aventis and Bristol-Myers Squibb, which were repeatedly discussed, once again surfaced.